Standard Analysis

AvantiCell offer a panel of standard 2D assays based upon key human cells and disease targets. These assays are focused on core functional indices and offer scalable delivery from one to hundreds of samples. We offer rapid turn-around of samples at competitive prices.

These assays can be used in a range of analyses including, but not limited to; nanosafety analysis, natural product testing, biosafety investigation, stem cell toxicity etc.

Analysis measurements and targets from; generic indices of cell health to cell-type specific activities at protein or gene expression level.

  • Viability
  • Cytotoxicity
  • Apoptosis
  • Proliferation

Customised Analysis

AvantiCell also provide specialist contract research services, which can be fully customised to meet client needs. Example customisation options include;

  • Customised options incorporating 3D cell models
  • Possible readouts include; fluorescence, luminescence, immunofluorescent staining, ELISA, PCR-based gene expression analysis
  • Client-commissioned isolation and banking of healthy, unusual or diseased human primary cell types
  • Development of customised analytical models
  • Bioactivity-driven purification of active components from complex mixtures

Disease Areas

Following expert development, AvantiCell are able to extend their standard analyses to provide  elaborate cell-based analysis focused on specific disease areas. 

Sample batches can be tailored to client requirements with highly reproducible, sensitive outputs. Scaled charges apply.

Applied successfully in preclinical evaluation of samples ranging from small molecule drug candidates to complex natural products and traditional medicines.

Further details below.

  • Fibrosis
  • Inflammation
  • Cancer
  • Diabetes (Type II)
  • Epithelial Barrier Models

Fibrosis

Our model evaluates test materials for their potential to cause tissue damage by induction of fibrosis or for their potential anti-fibrotic activity. 

Analysis is based upon fibroblast/myofibroblast conversion by cell population analysis, direct measurement of extracellular matrix deposition or upregulation of key genes involved in fibrosis pathogenesis.

Models of renal, lung and dermal fibrosis available.

Read our Technology Overview for more information.

Human Primary Renal Fibroblasts

Inflammation

Screening for inflammatory impact or anti-inflammatory potential. Analytical readouts: reactive oxygen species or pro-inflammatory cytokines.

Medium throughput system using human CD14+ monocyte, macrophage and/or dendritic cells.

Single cytokine or multiplexed cytokine bead-based analysis available.

Processes for the evaluation of nanosafety in development.

Human Macrophages

Cancer

Evaluates therapeutic potential in the treatment of cancer using conventional 2D models or 3D models with enhanced predictive value.

Analytical readouts ranging from simple indices of cell health to cancer-relevant molecular targets using cell marker or PCR-based gene expression to microarray-based gene expression profiling.

A range of primary cancer cells available for application in screening assays.

Human Primary Mammary Tumour Cells 

Diabetes (Type II)

Evaluates candidate therapeutic potential in terms of insulin sensitization of peripheral tissues using insulin-sensitive peripheral cells; human primary adipocytes (from pre-adipocyte precursors).

Measures glucose uptake as intracellular accumulation of fluorescent non-metabolised glucose analogue.

Human Differentiated Adipocytes

Epithelial Barrier Models

Barrier model incorporating human upper or lower respiratory airway primary cells. 

Effective in the evaluation of lung disease therapeutics. 

Healthy and diseased cell options available.

 

 

Human Primary Bronchial Tree Epithelial Cells

Testimonials

“We have done many projects with AvantiCell. Based on this, I can attest to their high level of science and high quality, trustworthy data. Communication is excellent and projects are completed within the agreed timelines. Highly recommended!”

 

Ruairí Mac Síomóin, 

Eolas Biosciences Co. Ltd.